These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

338 related articles for article (PubMed ID: 24051931)

  • 21. Safety issues in vasculitis: infections and immunizations in the immunosuppressed host.
    Isada CM
    Cleve Clin J Med; 2012 Nov; 79 Suppl 3():S38-45. PubMed ID: 23203645
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pharmacological treatments and infectious diseases in pediatric inflammatory bowel disease.
    Dipasquale V; Romano C
    Expert Rev Gastroenterol Hepatol; 2018 Mar; 12(3):237-247. PubMed ID: 28994306
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Opportunistic Infections in Biological Therapy, Risk and Prevention.
    Bryant PA; Baddley JW
    Rheum Dis Clin North Am; 2017 Feb; 43(1):27-41. PubMed ID: 27890172
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Updates on vaccinating the inflammatory bowel disease patient.
    Zullow S; Farraye FA
    Expert Rev Gastroenterol Hepatol; 2019 Mar; 13(3):229-239. PubMed ID: 30791761
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Serious infections in patients with inflammatory bowel disease receiving anti-tumor-necrosis-factor-alpha therapy: an Australian and New Zealand experience.
    Lawrance IC; Radford-Smith GL; Bampton PA; Andrews JM; Tan PK; Croft A; Gearry RB; Florin TH
    J Gastroenterol Hepatol; 2010 Nov; 25(11):1732-8. PubMed ID: 21039834
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Opportunistic infections in patients with inflammatory bowel disease: prevention and diagnosis.
    Viget N; Vernier-Massouille G; Salmon-Ceron D; Yazdanpanah Y; Colombel JF
    Gut; 2008 Apr; 57(4):549-58. PubMed ID: 18178610
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Risk of infections associated with biological treatment in inflammatory bowel disease.
    Andersen NN; Jess T
    World J Gastroenterol; 2014 Nov; 20(43):16014-9. PubMed ID: 25473153
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The Impact of Azathioprine-Associated Lymphopenia on the Onset of Opportunistic Infections in Patients with Inflammatory Bowel Disease.
    Vögelin M; Biedermann L; Frei P; Vavricka SR; Scharl S; Zeitz J; Sulz MC; Fried M; Rogler G; Scharl M
    PLoS One; 2016; 11(5):e0155218. PubMed ID: 27214202
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Risk of Infection and Types of Infection Among Elderly Patients With Inflammatory Bowel Disease: A Retrospective Database Analysis.
    Khan N; Vallarino C; Lissoos T; Darr U; Luo M
    Inflamm Bowel Dis; 2020 Feb; 26(3):462-468. PubMed ID: 30980714
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prevention of opportunistic infections in patients with inflammatory bowel disease and implications of the ECCO consensus in Belgium.
    Rahier JF; Moreels T; De Munter P; D'Haens G
    Acta Gastroenterol Belg; 2010; 73(1):41-5. PubMed ID: 20458849
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Impact of immunosuppressive therapy on hepatitis B vaccination in inflammatory bowel diseases.
    Belle A; Baumann C; Bigard MA; Zallot C; Gizard E; Guéant JL; Bronowicki JP; Peyrin-Biroulet L
    Eur J Gastroenterol Hepatol; 2015 Aug; 27(8):877-81. PubMed ID: 26121376
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Safety and Efficacy of Biologic Agents for the Management of Inflammatory Bowel Disease After Liver Transplantation.
    Shaikh SA; Fitzgerald L; Tischer S
    Pharmacotherapy; 2017 Dec; 37(12):1578-1585. PubMed ID: 28960437
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Screening for opportunistic infections and vaccination before introduction of biologic therapy].
    Sincić BM; Vince A
    Acta Med Croatica; 2013 Apr; 67(2):165-70. PubMed ID: 24471299
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Opportunistic Infection in Hospitalised Patients with Inflammatory Bowel Disease.
    Zhou JQ; Meng ZM; Zhang T; Jing XT; Gan HT
    J Coll Physicians Surg Pak; 2020 Oct; 30(10):1015-1020. PubMed ID: 33143819
    [TBL] [Abstract][Full Text] [Related]  

  • 35. How to manage the infectious risk under anti-TNF in inflammatory bowel disease.
    Culver EL; Travis SP
    Curr Drug Targets; 2010 Feb; 11(2):198-218. PubMed ID: 20210768
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Significant risk and associated factors of active tuberculosis infection in Korean patients with inflammatory bowel disease using anti-TNF agents.
    Kim ES; Song GA; Cho KB; Park KS; Kim KO; Jang BI; Kim EY; Jeon SW; Lee HS; Yang CH; Lee YK; Lee DW; Kim SK; Kim TO; Lee J; Kim HW; Jee SR; Park SJ; Kim HJ
    World J Gastroenterol; 2015 Mar; 21(11):3308-16. PubMed ID: 25805938
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The need for better preventative strategies for inflammatory bowel disease patients at risk of herpes zoster virus.
    Bye WA; Sparrow MP; Connor SJ; Andrews JM; Ellard K; Ng W; Hume G; Antoniades S; Walsh AJ
    Intern Med J; 2017 Nov; 47(11):1263-1269. PubMed ID: 28516725
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Imaging of opportunistic fungal infections in immunocompromised patient.
    Franquet T; Giménez A; Hidalgo A
    Eur J Radiol; 2004 Aug; 51(2):130-8. PubMed ID: 15246518
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Vaccinating the inflammatory bowel disease patient.
    Desalermos AP; Farraye FA; Wasan SK
    Expert Rev Gastroenterol Hepatol; 2015 Jan; 9(1):91-102. PubMed ID: 25160668
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Infectious and malignant complications of TNF inhibitor therapy in IBD.
    Targownik LE; Bernstein CN
    Am J Gastroenterol; 2013 Dec; 108(12):1835-42, quiz 1843. PubMed ID: 24042192
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.